Pediatric rheumatology

Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD

J RheumatolPublished Registry-based cohort study

Authors' conclusion

TNFi and MTX monotherapy are effective in adult JIA, with similar effectiveness to that shown in RA.

Study context

Population
Adult patients with juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA) from the Norwegian Antirheumatic Drug Register (NOR-DMARD)478 JIA, 4637 RA
Participants
358 / 2,292 / 120 / 2,345
Exposure
Adult JIA vs RA starting tumor necrosis factor inhibitors (TNFi) or methotrexate (MTX) monotherapy
  • JIA TNFin = 358
  • RA TNFin = 2,292reference
  • JIA MTX monotherapyn = 120
  • RA MTX monotherapyn = 2,345reference
Outcome
Change in disease activity (DAS28, Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), among others) from baseline
Follow-up
3, 6 and 12 months
Methodological detailsage- and gender-weighted analyses, adjusted for baseline disease activity, LUNDEX-corrected rates
  • Age- and gender-weighted analyses
  • Adjusted for baseline disease activity
  • LUNDEX-corrected rates

Main finding

As reported in the abstract

Change in disease activity from baseline
  • After baseline disease activity adjustment, no significant differences between JIA and RA for either treatment group
  • Adjusted for baseline disease activity

Observational data: associations, not effects.

Further findings

DAS28 remission · 12 months

ACR/EULAR remission · 12 months

Drug survival

Baseline disease activity

Lower in JIA than RA across treatment groups

DAS28 remission · 12 months

Similar between groups

American College of Rheumatology (ACR)/EULAR remission · 12 months

Similar between groups

Drug survival

Similar for JIA and RA in both treatment groups

Original publication

Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD. J Rheumatol. Published 15 November 2022. doi:10.3899/jrheum.220645

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.